Free tool
Drug Trial Radar
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
147
Recruiting, any sponsor type, condition "chronic obstructive pulmonary disease"
By trial status
The same filters, counted in each status. Pick one to switch.
- Recruiting147
- Completed1,659
147 trials
Showing 1 to 25, recently updated first.
- A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)Pivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT06878261 · 990 participants (planned) · Start Mar 25, 2025 · Primary completion Mar 13, 2029
Drug: Tezepelumab · For: Chronic Obstructive Pulmonary Disease (COPD)
Sites: Birmingham, Alabama; Cullman, Alabama; Phoenix, Arizona · 285 sites in all
- Trial Comparing the Safety and Efficacy of Two Different Oral VPV Doses With Placebo as Treatment for RV in Participants With COPDPivotal-lookingRecruiting
Altesa Biosciences, Inc.Industry
NCT07610395 · 180 participants (planned) · Start May 1, 2026 · Primary completion Nov 15, 2027
Drug: VPV 1000 mg; VPV 500 mg · For: Rhinovirus Infection
Sites: Mobile, Alabama; Tempe, Arizona; Inglewood, California · 46 sites in all
AeroRx Therapeutics Inc.Industry
NCT07896252 · 64 participants (planned) · Start Nov 1, 2026 · Primary completion Jun 2027
Drug: AERO-001; AERO-002 and 1 more · For: COPD; Chronic Obstructive Pulmonary Disease (COPD); Lung Disease Chronic and 1 more
Sites: London, United Kingdom; Manchester, United Kingdom
- A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary DiseasePivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT07082738 · 987 participants (planned) · Start Jun 27, 2025 · Primary completion Aug 31, 2027
Drug: AZD6793 · For: Chronic Obstructive Pulmonary Disease (COPD)
Sites: Birmingham, Alabama; Glendale, Arizona; Phoenix, Arizona · 369 sites in all
PfizerPfizer (PFE)
NCT07839884 · 1,360 participants (planned) · Start Oct 14, 2026 · Primary completion Apr 21, 2034
Drug: Tilrekimig · For: Moderate to Severe Chronic Obstructive Pulmonary Disease
Sites: San Diego, California; Winston-Salem, North Carolina; DuBois, Pennsylvania
- A Study to Investigate the Efficacy and Safety of GSK5784283 (Felcorekibart) Compared With Placebo in Participants With Moderate to Very Severe COPD (PERSIST COPD-1)Pivotal-lookingRecruiting
GlaxoSmithKlineGSK (GSK)
NCT07780669 · 624 participants (planned) · Start Aug 27, 2026 · Primary completion Jul 20, 2029
Drug: GSK5784283; Placebo and 1 more · For: Pulmonary Disease, Chronic Obstructive
Sites: Doral, Florida; Derby, Kansas; Lake Charles, Louisiana · 11 sites in all
- A Study to Assess the Efficacy and Safety of Co-administration of GSK3862995B With GSK5784283 in Adult Participants With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)Pivotal-lookingRecruiting
GlaxoSmithKlineGSK (GSK)
NCT07915791 · 279 participants (planned) · Start Oct 29, 2026 · Primary completion Mar 7, 2029
Drug: GSK3862995B; GSK5784283 and 1 more · For: Pulmonary Disease, Chronic Obstructive
Sites: Newport Beach, California; Miami, Florida; Derby, Kansas · 10 sites in all
- eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 InflammationPivotal-lookingRecruiting
GlaxoSmithKlineGSK (GSK)
NCT07177339 · 1,196 participants (planned) · Start Oct 20, 2025 · Primary completion Apr 2, 2029
Drug: Depemokimab; Placebo · For: Pulmonary Disease, Chronic Obstructive
Sites: Sheffield, Alabama; Tucson, Arizona; Escondido, California · 293 sites in all
- Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic PhenotypePivotal-lookingRecruiting
SanofiSanofi (SNY)
NCT07190209 · 942 participants (planned) · Start Sep 16, 2025 · Primary completion Nov 27, 2029
Drug: Lunsekimig; Placebo · For: Chronic Obstructive Pulmonary Disease
Sites: Chandler, Arizona; Phoenix, Arizona; Surprise, Arizona · 322 sites in all
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT07874815 · 2,136 participants (planned) · Start Nov 2, 2026 · Primary completion Apr 29, 2029
Drug: Ensifentrine; Standard of Care (SOC) · For: Pulmonary Disease, Chronic Obstructive
Sites: Hialeah Gardens, Florida; Loxahatchee Groves, Florida; Valparaiso, Indiana · 7 sites in all
Incyte CorporationIncyte (INCY)
NCT07124078 · 60 participants (planned) · Start May 20, 2026 · Primary completion Jan 31, 2029
Drug: INCA034176; Best available Treatment (BAT) · For: Chronic Graft-versus-host-disease
Sites: Duarte, California; Los Angeles, California; Palo Alto, California · 42 sites in all
- A Study of RO7830698 in Healthy Participants and Participants With Chronic Obstructive Pulmonary DiseasePivotal-lookingRecruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT07822334 · 104 participants (planned) · Start Oct 28, 2026 · Primary completion Oct 11, 2028
Drug: RO7830698; Placebo · For: Chronic Obstructive Pulmonary Disease (COPD); Healthy Participants
Sites: Wythenshawe, United Kingdom
- A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host DiseasePivotal-lookingRecruiting
Incyte CorporationIncyte (INCY)
NCT06585774 · 240 participants (planned) · Start Jan 21, 2025 · Primary completion Sep 28, 2027
Drug: INCA034176; Placebo and 1 more · For: Chronic Graft-versus-host-disease
Sites: Birmingham, Alabama; Tucson, Arizona; Duarte, California · 133 sites in all
- A Study to Investigate the Efficacy and Safety of GSK5784283 (Felcorekibart) Compared With Placebo in Participants With Moderate to Very Severe COPD (PERSIST COPD-2)Pivotal-lookingRecruiting
GlaxoSmithKlineGSK (GSK)
NCT07780656 · 624 participants (planned) · Start Sep 11, 2026 · Primary completion Jul 20, 2029
Drug: GSK5784283; Placebo and 1 more · For: Pulmonary Disease, Chronic Obstructive
Sites: Cape Coral, Florida; Greenacres City, Florida; Miami, Florida · 9 sites in all
- Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CPRecruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT07354074 · 50 participants (planned) · Start Apr 28, 2026 · Primary completion Feb 23, 2033
Drug: Asciminib single agent · For: Chronic Myelogenous Leukemia; Leukemia, Myelogenous, Chronic, Philadelphia Chromosome Positive
Sites: Chicago, Illinois; New Brunswick, New Jersey; New York, New York · 39 sites in all
National Cancer Institute (NCI)NIH
NCT04959175 · 320 participants (planned) · Start Sep 23, 2021 · Primary completion Apr 27, 2027
Drug: Mycophenolate Mofetil; Fludarabine and 4 more · For: Hematologic Neoplasms
Sites: Bethesda, Maryland; Philadelphia, Pennsylvania
National Cancer Institute (NCI)NIH
NCT05327023 · 430 participants (planned) · Start May 23, 2022 · Primary completion Jul 3, 2028
Drug: Cyclophosphamide; Busulfan and 3 more · For: Hematologic Neoplasms
Sites: Bethesda, Maryland
- A Study of 24 to 52 Weeks Treatment to Evaluate The Efficacy And Safety of Galvokimig in Study Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD) With Chronic BronchitisPivotal-lookingRecruiting
NCT07725939 · 402 participants (planned) · Start Jul 27, 2026 · Primary completion Jun 29, 2029
Drug: Galvokimig; Placebo · For: Chronic Obstructive Pulmonary Disease With Chronic Bronchitis
Sites: Encino, California; Westminster, California; Miami, Florida · 26 sites in all
- A Study to Investigate the Efficacy and Safety of Belumosudil Compared With Best Available Therapy in Participants Aged 12 Years or Older With Chronic Graft-versus-host DiseasePivotal-lookingRecruiting
SanofiSanofi (SNY)
NCT07771439 · 356 participants (planned) · Start Oct 12, 2026 · Primary completion Sep 14, 2029
Drug: Belumosudil · For: Chronic Graft Versus Host Disease
Sites: Amsterdam, Netherlands; Madrid, Spain · 3 sites in all
Zagazig UniversityGovernment (non-federal)
NCT07574879 · 54 participants (planned) · Start Mar 1, 2026 · Primary completion Sep 30, 2026
Drug: Eradication of Helcobacter Pylori · For: Chronic Obstructive Pulmonary Disease (COPD); With Poitive H Pylori
Sites: Zagazig, Egypt
- Oral Sildenafil for Exercise Capacity, Dyspnea and Cardiopulmonary Function in COPDPivotal-lookingRecruiting
University of AlbertaAcademic, hospital or other
NCT05061368 · 160 participants (planned) · Start Mar 1, 2022 · Primary completion May 2027
Drug: Sildenafil Citrate · For: Chronic Obstructive Pulmonary Disease
Sites: Edmonton, Canada
- A Study of Brenipatide (LY3537031) in Adult Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)Pivotal-lookingRecruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT07759245 · 606 participants (planned) · Start Aug 7, 2026 · Primary completion May 2028
Drug: Brenipatide; Placebo and 1 more · For: Pulmonary Disease, Chronic Obstructive
Sites: Birmingham, Alabama; Newport Beach, California; San Diego, California · 127 sites in all
Connect Biopharm LLCIndustry
NCT07705737 · 40 participants (planned) · Start Aug 21, 2026 · Primary completion Dec 2026
Drug: Rademikibart · For: Asthma Acute; COPD Exacerbation Acute
Sites: Miami, Florida; St Louis, Missouri · 3 sites in all
- Ex Vivo-Expanded Regulatory T Cells Plus Low-Dose Interleukin-2 for Steroid-Refractory Chronic GVHDRecruiting
Sarah Nikiforow, MDAcademic, hospital or other
NCT06991361 · 21 participants (planned) · Start May 29, 2026 · Primary completion May 1, 2029
Drug: EVE-Treg · For: Graft Versus Host Disease (cGvHD)
Sites: Boston, Massachusetts
M.D. Anderson Cancer CenterAcademic, hospital or other
NCT06434363 · 47 participants (planned) · Start Jul 31, 2024 · Primary completion Dec 31, 2028
Drug: Tafasitamab; Fludarabine phosphate and 2 more · For: Autoimmune Disorders; Systemic Sclerosis; Systemic Lupus Erythematosus and 2 more
Sites: Houston, Texas · 2 sites in all
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.